The expression of CD274, which encodes programmed death 1 (PD-L1), a ligand for the immunological checkpoint protein PD-1, has been observed to be increased in ATCs, proposing novel therapeutic options for ATC through the utilization of immunotherapy (48). This evidence concerns the gene CD274 and Ehlers-Danlos syndrome, musculocontractural type.